3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
6
pembrolizumab
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
Drug Therapy
4
fludarabine
3
XELOX
3
Specimen Handling
3
Laparoscopy
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07407465
2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
42 enrolled